Brief: Cingulate Presents Positive Phase 3 Results for CTx-1301
28/10/2025 12:22
Oct 28 (Reuters) - Cingulate Inc CING.O: CINGULATE PRESENTS POSITIVE PHASE 3 RESULTS FOR CTX-1301 DEMONSTRATING STATISTICALLY SIGNIFICANT EFFICACY AND ENTIRE ACTIVE-DAY SYMPTOM CONTROL Source text: ID:nGNX57NmLC Further company coverage: CING.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cingulate
See all newsBrief: Cingulate Announces Publication Of Phase 3 Adhd Trial Results In Journal Of Child And Adolescent Psychopharmacology
NASDAQ RESUMED AT 09:39 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM
NASDAQ RESUMED AT 08:30 AM
FDA declines to approve Cingulate's ADHD treatment over manufacturing issues (updated)